Company profilePharmaceutical#177 of 1,318 in Pakistan2 DRAP alerts

GSK Pakistan Limited

Pharmaceutical company · 101 brands · 154 molecules

Ranked #15 of 62 companies in Neuro

101 registered products 38 pharmaceutical brands 154 distinct molecules 2 DRAP alerts

Company overview

101
registered products
38
pharmaceutical brands
154
distinct molecules
12
therapeutic classes
2
DRAP alerts

GSK Pakistan Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 101 product registrations across 154 distinct molecules. It is the 177th largest registrant in Pakistan by product count, and ranks 15th of 62 in Neuro. Its portfolio is concentrated in Neuro and Skin Conditions. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by GSK

20 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Psychostimulants, Nootropic & Neurotonic 2
Antiinflammatory Agents, Corticosteroids 1
Antiinflammatory Agents And Antiinfectives In Combination 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

3
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20263

Top molecules by brand count

Neomycin6 brands
Eye5 brands
Salbutamol4 brands
Lamotrigine4 brands
Pyridoxine3 brands
Riboflavin3 brands
Folic Acid3 brands
Thiamine3 brands

Therapeutic classes

Neuro · 6Skin Conditions · 5Anti-Infectives · 5Vaccine · 5Anti-Acne Preparations · 4Antihistamines For Systemic Use · 4Corticosteroid Combinations, Topical · 4Multivitamin, Combinations · 4Antivirals For Systemic Use · 3Antineoplastics · 3Allergy · 3Other Bacterial And Viral Vaccines · 3

Conditions treated

General Infections · 4Acne/Topical · 3Conventional Agents · 3Anxiety/Depression/Insomnia · 2Viral Infection/Hepatitis · 1Oncology · 1Fever/Pain/Flu · 1Infection/Allergy · 1Neuropathic Pain/Epilepsy/Convulsion · 1Hypothyroidism · 1Muscle Relaxant/Spasm · 1Schizophrenia/Psychosis · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official33 products · Rs 115.15 – Rs 57,906.24
DVAGO30 products · Rs 21.9 – Rs 1,211
Servaid44 products · Rs 20.3 – Rs 4,828.74
Median across source: Rs 197.12

Regulatory record

2 alerts in the DRAP feed we track.

Recall Alert: Voluntary Recall of 36 Batches of Motival Tablets (Reg # 004539) Manufacture
2025-02-18
Drug Product Recall: M/S. Gsk Pakistan Limited, Karachi issued voluntary recall of Nootrop
2021-11-29

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GlaxoSmithKline Pakistan Limited holds 122 molecules not in this portfolio
AcetylcysteineAcyclovirAcyclovir InfAlbendazoleAlbuterolAllopurinol
ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 150 molecules not in this portfolio
AlbuterolAmikacinAminophyllineAmlodipineAmlodipine BaseAmmonium Chloride
VALOR PHARMACEUTICALS holds 149 molecules not in this portfolio
000 I.UAcetylcysteineAcitretinAcyclovirAdapaleneAdaplene

Get the full profile for GSK

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.